Kit "HEPA-D-test-Q" for qualitative and quantitative detection of hepatitis D virus has been registered in Russia

The TestGene company has registered the kit "HEPA-D-test-Q" for qualitative and quantitative detection of hepatitis D virus RNA.

The kit is used for diagnostics of viral hepatitis D and evaluation of the effectiveness of the therapy.

The HDV virus occurs in about 5% of people with hepatitis B, can spread rapidly and increases the risk of cirrhosis and liver cancer. Chronic hepatitis D develops in 70-90% of cases of HDV superinfection.

"Co-infection with hepatitis B and D viruses is considered the most severe form of chronic hepatitis, as it often leads to the development of carcinoma and death. The test system for qualitative and quantitative analysis of hepatitis D developed by us will make it possible to detect this infection timely and monitor the dynamics of treatment. And the widespread introduction of this test into the scheme of diagnostics will contribute to the accumulation of statistical data on the prevalence of this virus," says Denis Viktorov, Director of Science at TestGene, Candidate of Biological Sciences.

In Russia, due attention is not paid to detection of hepatitis D and determination of viral load. Until recently, chronic hepatitis D was considered untreatable. However, a medication for treatment of chronic hepatitis D was registered in the Russian Federation in 2019.

The new highly specific test system "HEPA-D-test-Q" produced by TestGene has no analogues on the market and makes it possible to detect the HDV virus and viral load. The material for the test is plasma or whole peripheral blood. The test system is compatible with all open type cyclers (with two detection channels).

All news